MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Thermo Fisher Scientific Inc

Gesloten

SectorGezondheidszorg

469.72 -3.98

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

468.06

Max

487.64

Belangrijke statistieken

By Trading Economics

Inkomsten

194M

1.8B

Verkoop

795M

11B

K/W

Sectorgemiddelde

30.121

63.778

EPS

6.1

Dividendrendement

0.35

Winstmarge

16.007

Werknemers

125,000

EBITDA

377M

3B

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+36.36% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

0.35%

2.39%

Volgende Winsten

23 apr 2025

Volgende dividenddatum

15 apr 2025

Volgende Ex Dividend datum

13 jun 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-40B

189B

Vorige openingsprijs

473.7

Vorige sluitingsprijs

469.72

Nieuwssentiment

By Acuity

33%

67%

106 / 386 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

Thermo Fisher Scientific Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

25 feb 2025, 14:05 UTC

Acquisities, Fusies, Overnames

Thermo Fisher Scientific to Acquire Solventum's Filtration Unit, Confirming WSJ Report

30 jan 2025, 11:43 UTC

Winsten

Thermo Fisher Scientific Profit, Revenue Rose in 4Q

23 okt 2024, 10:43 UTC

Winsten

Thermo Fisher Raises Floor of Earnings Target After Steady 3Q Sales

25 feb 2025, 14:09 UTC

Acquisities, Fusies, Overnames

Thermo Fisher Strikes Deal for Solventum's Filtration Unit -- WSJ

25 feb 2025, 13:41 UTC

Acquisities, Fusies, Overnames

Solventum: Transaction Is Expected to Be Completed by End of 2025 >SOLV

25 feb 2025, 13:40 UTC

Acquisities, Fusies, Overnames

Solventum Expects Estimated $3.4 B in Net Proceeds >SOLV

25 feb 2025, 13:40 UTC

Acquisities, Fusies, Overnames

Solventum: Deal Strengthens Balance Sheet With Proceeds to Be Used Primarily for Debt Paydown >SOLV

25 feb 2025, 13:40 UTC

Acquisities, Fusies, Overnames

Solventum Expects Deal to Be Neutral to 2025 EPS >SOLV

25 feb 2025, 13:40 UTC

Acquisities, Fusies, Overnames

Solventum: Deal Accelerates Business Transformation and Sharpens Focus on Strategic Areas for Growth

25 feb 2025, 13:39 UTC

Acquisities, Fusies, Overnames

Solventum Announces Sale of Its Purification & Filtration Business to Thermo Fisher Scientific Inc. for $4.1B

25 feb 2025, 13:33 UTC

Acquisities, Fusies, Overnames

Thermo Fisher: Solventum Business Generated About $1 Billion Revenue in 2024 >TMO

25 feb 2025, 13:32 UTC

Acquisities, Fusies, Overnames

Thermo Fisher to Buy Solventum Purification, Filtration Business for About $4.1 Billion Cash >TMO SOLV

25 feb 2025, 13:32 UTC

Acquisities, Fusies, Overnames

Thermo Fisher Scientific To Acquire Solventum's Purification And Filtration Business >TMO

24 feb 2025, 23:03 UTC

Acquisities, Fusies, Overnames

Thermo Fisher Scientific Nears Deal for Solventum's Purification and Filtration Business, Sources Say -- WSJ

24 feb 2025, 23:03 UTC

Top Nieuws
Acquisities, Fusies, Overnames

Thermo Fisher Nears Deal for Solventum Filtration Unit -- WSJ

24 feb 2025, 23:03 UTC

Acquisities, Fusies, Overnames

Deal Could be Announced This Week, Sources Say -- WSJ

24 feb 2025, 23:03 UTC

Acquisities, Fusies, Overnames

Transaction Could Value Solventum Filtration Business Between $3.5B to $4B, Sources Say -- WSJ

30 jan 2025, 11:06 UTC

Winsten

Thermo Fisher: In a Great Position to Deliver Excellent Performance in 2025 >TMO

30 jan 2025, 11:05 UTC

Winsten

Thermo Fisher: Will Provide 2025 Fincl Guidance During Earnings Conference Call Thursday Morning >TMO

30 jan 2025, 11:00 UTC

Winsten

Thermo Fisher 4Q Rev $11.4B >TMO

30 jan 2025, 11:00 UTC

Winsten

Thermo Fisher 4Q EPS $4.78 >TMO

30 jan 2025, 11:00 UTC

Winsten

Thermo Fisher 4Q Core Organic Revenue Up 5% >TMO

30 jan 2025, 11:00 UTC

Winsten

Thermo Fisher 4Q Net $1.83B >TMO

30 jan 2025, 11:00 UTC

Winsten

Thermo Fisher 4Q Adj EPS $6.10 >TMO

16 dec 2024, 22:03 UTC

Top Nieuws

Novo's New Deal May End Wegovy Shortages. It Could Reshape the Pharma Industry Along the Way. -- Barrons.com

23 okt 2024, 10:02 UTC

Winsten

Thermo Fisher Had Seen 2024 Adjusted EPS $21.29-$22.07 >TMO

23 okt 2024, 10:02 UTC

Winsten

Thermo Fisher Backs 2024 View of Rev $42.4B-$43.3B >TMO

23 okt 2024, 10:00 UTC

Winsten

Thermo Fisher 3Q Core Organic Revenue 0% >TMO

23 okt 2024, 10:00 UTC

Winsten

Thermo Fisher 3Q EPS $4.25 >TMO

23 okt 2024, 10:00 UTC

Winsten

Thermo Fisher 3Q Adj EPS $5.28 >TMO

Peer Vergelijking

Prijswijziging

Thermo Fisher Scientific Inc Prognose

Koersdoel

By TipRanks

36.36% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 666.88 USD  36.36%

Hoogste 715 USD

Laagste 570 USD

Gebaseerd op 17 Wall Street-analisten die 12-maands prijsdoelen bieden voor Thermo Fisher Scientific Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

17 ratings

14

Buy

3

Hold

0

Sell

Technische score

By Trading Central

481.21 / 513.42Steun & Weerstand

Korte Termijn

Strong Bearish Evidence

Gemiddeld Termijn

Weak Bearish Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

106 / 386 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Thermo Fisher Scientific Inc

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. It has a collaboration agreement with Mainz Biomed N.V. for the development of colorectal cancer screening product. Thermo Fisher Scientific Inc. was founded in 1956 and is headquar